The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …

Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …

Introduction Treatment-related neurotoxicity is a common side effect in cancer patients.
However, few data are available regarding the risk of several neurotoxicities in patients …

Expanding use of immune‐checkpoint inhibitors (ICIs) underscores the importance of
accurate diagnosis and timely management of neurological immune‐related adverse events …

Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour
immunity, can trigger neurological adverse events closely resembling paraneoplastic …

Objective To explore the spectrum of skeletal muscle and nerve pathology of patients who
died after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …